We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Merus NV (MRUS) EUR0.09

Sell:$42.49 Buy:$42.66 Change: $0.13 (0.29%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$42.49
Buy:$42.66
Change: $0.13 (0.29%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$42.49
Buy:$42.66
Change: $0.13 (0.29%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Contact details

Address:
Uppsalalaan 17, 3rd & 4th floor
UTRECHT
3584 CT
Netherlands
Telephone:
+31 (85) 0162500
Website:
https://merus.nl/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MRUS
ISIN:
NL0011606264
Market cap:
$2.90 billion
Shares in issue:
68.46 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Netherlands
Currency:
US dollar
Indices:
n/a

Key personnel

  • Sven Lundberg
    President, Chief Executive Officer, Executive Director
  • Gregory Perry
    Chief Financial Officer
  • Peter Silverman
    Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
  • Fabian Zohren
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.